ERBB2 and neoplasm: Current CAR clinical trials are expanding to target other tumor-associated markers including GD2 (10), BCMA (11), CD20, CD30, CD33, CD7, HER2 (human epidermal growth factor receptor 2), and mesothelin (12–17).